Find the latest pharmaceutical market place for formulations enquiry about Duloxetine Hydrochloride on PharmaCompass.com.

Various Finished Dosage Formulations needed in Brazil [ENA12556]

A company that deals in the research, development & trading of health products is looking for suppliers of Various Finished Dosage Formulations for commercial purpose. The suppliers must support this enquiry with CTD Dossier, ANVISA, DMF & PIC/s GMP.
1. Infliximab (100 mg & 10 mg) Lyophilized Vials.
2. Bevacizumab (25 mg in 4 ml & 25 mg in 16 ml) Infusions.
3. Duloxetine HCl (60 mg & 30 mg) Slow release Capsules. The required quantity is 50 million units & 10 million units respectively.
4. Dabigatran (110 mg & 150 mg) Capsules. The required quantity is 28 million units & 10 million units respectively.

Reply

31 Jan 2022

Enquiry// Duloxetine Pellets (100kg-200kg) needed in Pakistan [ENA01719]

A rapidly growing pharmaceutical organisation based in Pakistan is looking for the suppliers of Duloxetine Pellets (100kg-200kg). Interested suppliers must support this Certificate of Analysis and the suppliers must contact Zeeshan Rafi via E-mail: Zeeshan.rafi@ted.com.pk or Tel: +92-21-35110017 or +92-21-35110018.

Reply

31 Aug 2018

Enquiry// Duloxetine Tablets (20mg and 30mg) needed in Japan [ENA01538]

An intensively growing pharmaceutical company based in Japan is looking for the suppliers of Duloxetine Tablets (20mg and 30mg) for domestic consumption.

Reply

17 Aug 2018

Enquiry// Duloxetine Tablets (20mg and 30mg) needed in Japan [ENA01503]

An intensively growing pharmaceutical company based in Japan is looking for the suppliers of Duloxetine Tablets (20mg and 30mg). Interested suppliers must contact Hashimoto via E-mail: t_hashimoto@riverson.co.jp.

Reply

15 Aug 2018

Enquiry// Looking for Marketing Partners for various Finished Dose Formulations in China [ENA00365]

Inventia Healthcare, one of the leading drug delivery companies in India is searching for partners for its US FILED Products for the Chinese Market:

Products developed against international innovator:
1. Gliclazide 30/60 mg ER Tablets
2. Metformin HCl 500/750/1000 mg SR Tablets.
3. Lansoprazole 15/30 mg EC Capsules
4. Metoprolol 25/50/100/200 mg ER Tablets
5. Olmesartan Medoxomil 5/20/40 mg Tablets
6. Telmisartan 20/40/80 mg Tablets
7. Telmisartan + Hydrochlorthiazide 40/12.5, 80/12.5, 80/25 mg Tablets
8. Duloxetine 20/30/60 mg DR Capsules
9. Venlafaxine 37.5/75/150 mg SR Capsules
10. Darifenacin Hydrobromide 7.5/15 mg ER Tablets
11. Felodipine 2.5/5/10 mg ER Tablets
12. Rosuvastatin 5 /10/20/40 mg Tablets
13. Iloperidone 1/2/4/6/8/10/12 mg Tablets
14. Paliperidone 1.5/3/6/9 mg ER Tablets
15. Tolterodine Tartrate 2/4 mg ER Capsules

New Products Under development
1. Sitagliptin + Metformin 50/500 mg, 50/1000 mg Tablets
2. Sitagliptin + Metformin ER 50/500 mg, 50/1000; 100/1000 mg Tablets
3. Dapagliflozin 5/10 mg Tablets
4. Mesalamine 1.2 mg DR Tablets
5. Ezetimibe 10 mg Tablets
Interested partners can contact Sumeet Mehta at sumeet.mehta@inventiahealthcare.com or call +91-9930922062.

Reply

12 Jun 2017

Enquiry// Looking for Marketing Partners for various Finished Dose Formulations across Emerging Markets [ENA00236...

Inventia Healthcare, is searching for partners for:
DEVELOPED PRODUCTS
South East Asia, CIS, Australia, Middle East & Africa, LATAM:-
1. Lansoprazole 15/30 mg EC Capsules
2. Metoprolol 25/50/100/200 mg ER Tablets
3. Olmesartan Medoxomil 5, 20, 40 mg Tablets
4. Telmisartan 20/40/80 mg Tablets
5. Telmisartan + Hydrochlorthiazide 40/12.5, 80/12.5, 80/25 mg Tablets
6. Duloxetine 20/30/60 mg DR Capsules
7. Venlafaxine 37.5/75/150 mg SR Capsules
8. Darifenacin Hydrobromide 7.5/15 mg ER Tablets

South East Asia, CIS, Australia, Middle East & Africa, LATAM Argentina, Uruguay, Paraguay, Chile:-
1. Metformin HCl 750 mg SR Tablets

South East Asia, CIS, Australia, Middle East & Africa, LATAM, India:-
1. Gliclazide 30/60 mg ER Tablets
2. Felodipine 2.5/5/10 mg ER Tablets
3. Rosuvastatin 5 /10 /20/40 mg Tablets

Dossier for South East Asia, CIS, Australia Korea, Taiwan, China, Russia, Ukraine, Kazakhstan, Uzbekistan, Hong Kong, Thailand, Middle East & Africa, South Africa, GCC, Iraq, Algeria, LATAM, Argentina, Uruguay, Paraguay, Chile, India:-
1. Metformin HCl 500 mg SR Tablets

Dossier for South East Asia, CIS, Australia, Korea, Taiwan, China, Russia, Ukraine, Kazakhstan, Uzbekistan, Hong Kong, Thailand, Malaysia, LATAM, Argentina, Uruguay, Paraguay, Chile, All countries in SEA, CIS, Australia, Middle East & Africa:-
1. Metformin HCl 1000 mg SR Tablets
Interested partners can contact @ https://www.pharmacompass.com/api-manufacturers/inventia-healthcare-private-limited

Reply

02 Mar 2017

EU CTD Dossiers Available // Looking for Marketing Partners in the EU for various products [ENA00142]

Inventia Healthcare, one of the leading drug delivery companies in India is searching for partners in Europe for the following products which are at various stages of development -

Approved MA:
1. Duloxetine DR Capsules 30 mg/ 60 mg

Products Under development:
1. Gliclazide MR Tablets 30 mg/ 60 mg - EU fillable dossier will be ready by Oct 2017
2. Ezetimibe 10 mg Tablets - EU fillable dossier will be ready by Dec 2017

Products developed against international innovators and easily extendable to EU
1. Metformin SR Tablets 500 mg
2. Metformin SR Tablets 750 mg
3. Metformin SR Tablets 1000 mg
4. Darifenacin ER tablets 7.5 mg/ 15 mg

New Products Under development for EU
1. Rivaroxaban Tablets 10mg, 15 mg, 20 mg: will be ready by Q3 2019
2. Sitagliptin + Metformin: Target to be ready by Q2 2022
3. Mesalamine 1200 Gm Tablets - Target to be ready by Q3 2019

Interested partners should contact Priyanka Dhanjal at priyanka.dhanjal@inventiahealthcare.com or call +919987152274

Reply

02 Jan 2017